Jul 10, 2023 / 12:30PM GMT
Operator
Good day and thank you for standing by. Welcome to the Nanobiotix License Agreement with Janssen Pharmaceutica NV, one of Janssen Pharmaceutical Companies of J&J, for the co-development and commercialization of NBTXR3 conference call. A slide presentation accompanying this call can be found on the investor section of the company's website at www.nanobiotix.com. (Operator Instructions) Please be advised that today's conference is being recorded. At this point, I'll turn the call over to Craig West, Senior Vice President of Investor Relations of Nanobiotix.
Craig West - Nanobiotix SA - SVP, IR
Thank you, Melissa. Good afternoon and good morning, everyone, and welcome to the Nanobiotix Conference call to discuss our worldwide agreement with Janssen for the co-development and commercialization of our potentially first-in-class radioenhancer, NBTXR3. By Janssen, we mean Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of J&J. Slides for today's call can be found on the
Nanobiotix SA License Agreement with Janssen Briefing Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot